Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 10
Submit an article Journal homepage
62
Views
6
CrossRef citations to date
0
Altmetric
Theme: Stents & Devices - Review

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation

Dong-Ho Shin Severance Cardiovascular Hospital & Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea
&
Myeong-Ki Hong Severance Cardiovascular Hospital & Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. mkhong61@ yuhs.ac
Pages 1273-1285 | Published online: 10 Jan 2014

References

  • Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334(17), 1084–1089 (1996).
  • Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N. Engl. J. Med. 339(23), 1665–1671 (1998).
  • Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 98(16), 1597–1603 (1998).
  • Urban P, Macaya C, Rupprecht HJ et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 98(20), 2126–2132 (1998).
  • Cutlip DE, Baim DS, Ho KK et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103(15), 1967–1971 (2001).
  • Mehta SR, Yusuf S, Peters RJ et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358(9281), 527–533 (2001).
  • Steinhubl SR, Berger PB, Mann JT 3rd et al.; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288(19), 2411–2420 (2002).
  • Sabatine MS, Cannon CP, Gibson CM et al.; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294(10), 1224–1232 (2005).
  • Ielasi A, Al-Lamee R, Colombo A. Stent thrombosis and duration of dual antiplatelet therapy. Curr. Pharm. Des. 16(36), 4052–4063 (2010).
  • FDA Public Health Web Notification: Updated Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER™ Sirolimus-eluting Coronary Stent. FDA.
  • McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364(9444), 1519–1521 (2004).
  • Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J. Am. Coll. Cardiol. 45(12), 2088–2092 (2005).
  • Kuchulakanti PK, Chu WW, Torguson R et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113(8), 1108–1113 (2006).
  • Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667–678 (2007).
  • Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am. J. Med. 119(12), 1056–1061 (2006).
  • Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 115(11), 1440–1455; discussion 1455 (2007).
  • Farb A, Boam AB. Stent thrombosis redux – the FDA perspective. N. Engl. J. Med. 356(10), 984–987 (2007).
  • Jeremias A, Sylvia B, Bridges J et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109(16), 1930–1932 (2004).
  • Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364(9434), 583–591 (2004).
  • Moreno R, Fernández C, Hernández R et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J. Am. Coll. Cardiol. 45(6), 954–959 (2005).
  • Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J. Am. Coll. Cardiol. 45(6), 941–946 (2005).
  • Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356(10), 998–1008 (2007).
  • Kastrati A, Mehilli J, Pache J et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356(10), 1030–1039 (2007).
  • Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193–202 (2006).
  • Finn AV, Nakazawa G, Joner M et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler. Thromb. Vasc. Biol. 27(7), 1500–1510 (2007).
  • Nakazawa G, Finn AV, Joner M et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118(11), 1138–1145 (2008).
  • Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293(17), 2126–2130 (2005).
  • Pfisterer M, Brunner-La Rocca HP, Buser PT et al.; BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J. Am. Coll. Cardiol. 48(12), 2584–2591 (2006).
  • Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J. Am. Coll. Cardiol. 47(1), e1–e121 (2006).
  • King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al.; 2005 WRITING COMMITTEE MEMBERS. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117(2), 261–295 (2008).
  • Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am. J. Cardiol. 101(7), 960–966 (2008).
  • Berger PB, Bhatt DL, Fuster V et al.; CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121(23), 2575–2583 (2010).
  • Brilakis ES, Banerjee S, Berger PB. Perioperative management of patients with coronary stents. J. Am. Coll. Cardiol. 49(22), 2145–2150 (2007).
  • Bigalke B, Seizer P, Geisler T, Lindemann S, Gawaz M, May AE. Perioperative antiplatelet therapy in patients at risk for coronary stent thrombosis undergoing noncardiac surgery. Clin. Res. Cardiol. 98(5), 335–339 (2009).
  • To AC, Armstrong G, Zeng I, Webster MW. Noncardiac surgery and bleeding after percutaneous coronary intervention. Circ. Cardiovasc. Interv. 2(3), 213–221 (2009).
  • Nikolsky E, Stone GW, Kirtane AJ et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J. Am. Coll. Cardiol. 54(14), 1293–1302 (2009).
  • Doyle BJ, Rihal CS, Gastineau DA, Holmes DR Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J. Am. Coll. Cardiol. 53(22), 2019–2027 (2009).
  • Berger JS, Bhatt DL, Steg PG et al. Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am. Heart J. 162(1), 98–105.e1 (2011).
  • Campo G, Saia F, Guastaroba P et al. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch. Intern. Med. 171(21), 1948–1949 (2011).
  • Ndrepepa G, Schuster T, Hadamitzky M et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 125(11), 1424–1431 (2012).
  • Levine GN, Bates ER, Blankenship JC et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58(24), e44–e122 (2011).
  • Musumeci G, Di Lorenzo E, Valgimigli M. Dual antiplatelet therapy duration: what are the drivers? Curr. Opin. Cardiol. 26(Suppl. 1), S4–S14 (2011).
  • Bolognese L, Angiolillo DJ. Unravelling the benefit against the risk of long-term dual antiplatelet therapy. Curr. Opin. Cardiol. 26(Suppl. 1), S22–S30 (2011).
  • Eisenstein EL, Anstrom KJ, Kong DF et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297(2), 159–168 (2007).
  • Brar SS, Kim J, Brar SK et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J. Am. Coll. Cardiol. 51(23), 2220–2227 (2008).
  • van Werkum JW, Heestermans AA, Zomer AC et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J. Am. Coll. Cardiol. 53(16), 1399–1409 (2009).
  • Airoldi F, Colombo A, Morici N et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116(7), 745–754 (2007).
  • Schulz S, Schuster T, Mehilli J et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur. Heart J. 30(22), 2714–2721 (2009).
  • Kimura T, Morimoto T, Nakagawa Y et al.; j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 119(7), 987–995 (2009).
  • Shin DH, Chae I-H, Youn T-J et al. Reasonable duration of clopidogrel use after drug-eluting stent implantation in Korean patients. Am. J. Cardiol. 104(12), 1668–1673 (2009).
  • Wijns W, Kolh P, Danchin N et al. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio–Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), Guidelines on myocardial revascularization. Eur. Heart J. 31(20), 2501–2555 (2010).
  • Banerjee S, Varghese C, Samuel J et al. Comparison of the impact of short(<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality. Am. J. Cardiol. 102(9), 1159–1162 (2008).
  • Tanzilli G, Greco C, Pelliccia F et al. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am. J. Cardiol. 104(10), 1357–1361 (2009).
  • Park DW, Yun SC, Lee SW et al. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc. Interv. 1(5), 494–503 (2008).
  • Park SJ, Park DW, Kim YH et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N. Engl. J. Med. 362(15), 1374–1382 (2010).
  • Valgimigli M, Campo G, Monti M et al.; Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 125(16), 2015–2026 (2012).
  • Kandzari DE, Barker CS, Leon MB et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC. Cardiovasc. Interv. 4(10), 1119–1128 (2011).
  • Eriksson P. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the “Emperor’s New Clothes” revisited. Eur. Heart J. 25(9), 720–722 (2004).
  • Gwon HC, Hahn JY, Park KW et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 125(3), 505–513 (2012).
  • Spertus JA, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113(24), 2803–2809 (2006).
  • Stettler C, Allemann S, Wandel S et al. Drug eluting and bare-metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 337, a1331 (2008).
  • Urban P, Gershlick AH, Guagliumi G et al.; e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 113(11), 1434–1441 (2006).
  • Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49(24), 2312–2317 (2007).
  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
  • Sabatine MS, Cannon CP, Gibson CM et al.-CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352(12), 1179–1189 (2005).
  • Bhatt DL, Fox KA, Hacke W et al.; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354(16), 1706–1717 (2006).
  • Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J. Am. Coll. Cardiol. 59(24), 2159–2164 (2012).
  • Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl.J. Med. 357(20), 2001–2015 (2007).
  • Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120(5), 391–399 (2009).
  • Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 123(7), 779–797 (2011).
  • Serruys PW, Onuma Y, Dudek D et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J. Am. Coll. Cardiol. 58(15), 1578–1588 (2011).
  • Byrne RA, Kastrati A, Massberg S et al.; ISAR-TEST 4 Investigators. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J. Am. Coll. Cardiol. 58(13), 1325–1331 (2011).
  • Stefanini GG, Kalesan B, Serruys PW et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378(9807), 1940–1948 (2011).
  • Aoki J, Serruys PW, van Beusekom H et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J. Am. Coll. Cardiol. 45(10), 1574–1579 (2005).
  • Räber L, Magro M, Stefanini GG et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 125(9), 1110–1121 (2012).
  • Baber U, Mehran R, Sharma SK et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J. Am. Coll. Cardiol. 58(15), 1569–1577 (2011).
  • Kolandaivelu K, Swaminathan R, Gibson WJ et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123(13), 1400–1409 (2011).
  • Butler MJ, Eccleston D, Clark DJ et al.; Melbourne Interventional Group. The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. Am. Heart J. 157(5), 899–907 (2009).
  • Kim JS, Hong MK, Fan C et al. Intracoronary thrombus formation after drug-eluting stents implantation: optical coherence tomographic study. Am. Heart J. 159(2), 278–283 (2010).
  • Mehran R, Pocock SJ, Stone GW et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur. Heart J. 30(12), 1457–1466 (2009).
  • Eshaghian S, Kaul S, Amin S, Shah PK, Diamond GA. Role of clopidogrel in managing atherothrombotic cardiovascular disease. Ann. Intern. Med. 146(6), 434–441 (2007).
  • Subherwal S, Bach RG, Chen AY et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 119(14), 1873–1882 (2009).
  • Mehta SK, Frutkin AD, Lindsey JB et al. National Cardiovascular Data Registry. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ. Cardiovasc. Interv. 2(3), 222–229 (2009).
  • Mehran R, Pocock SJ, Nikolsky E et al. A risk score to predict bleeding in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 55(23), 2556–2566 (2010).
  • Dauerman HL, Rao SV, Resnic FS, Applegate RJ. Bleeding avoidance strategies. Consensus and controversy. J. Am. Coll. Cardiol. 58(1), 1–10 (2011).
  • Montalescot G, Salette G, Steg G et al. Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention. Int. J. Cardiol. 150(1), 79–83 (2011).
  • Tsai TT, Messenger JC, Brennan JM et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J. Am. Coll. Cardiol. 58(18), 1859–1869 (2011).
  • Cayla G, Hulot JS, O’Connor SA et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306(16), 1765–1774 (2011).
  • Gori AM, Marcucci R, Migliorini A et al. Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J. Am. Coll. Cardiol. 52(9), 734–739 (2008).
  • Lee SP, Park KW, Shin DH et al. Efficacy of predicting thrombotic events with combination of dual point-of-care testing (POCT) after drug-eluting stent implantation for coronary heart disease: results from the CILON-T randomized trial POCT substudy. J. Atheroscler. Thromb. 18(10), 914–923 (2011).
  • Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J. Thromb. Haemost. 8(10), 2140–2148 (2010).
  • Breet NJ, van Werkum JW, Bouman HJ et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart 97(12), 983–990 (2011).
  • Campo G, Fileti L, de Cesare N et al.; 3T/2R Investigators. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention:a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J. Am. Coll. Cardiol. 56(18), 1447–1455 (2010).
  • Marcucci R, Paniccia R, Antonucci E et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am. J. Cardiol. 98(9), 1156–1159 (2006).
  • Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167(15), 1593–1599 (2007).
  • Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336(7637), 195–198 (2008).
  • Schömig A, Dibra A, Windecker S et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J. Am. Coll. Cardiol. 50(14), 1373–1380 (2007).
  • Finn AV, Joner M, Nakazawa G et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115(18), 2435–2441 (2007).
  • de Smet BJ, Zijlstra F. A look at drug eluting stents with optical coherence tomography. Eur. Heart J. 28(8), 918–919 (2007).
  • Guagliumi G, Sirbu V. Optical coherence tomography: high resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter. Cardiovasc. Interv. 72(2), 237–247 (2008).
  • Kim JS, Wallace-Bradley D, Alviar CL et al. Correlation of angiographic late loss with neointimal proliferation in stents evaluated by OCT and histology in porcine coronary arteries. JACC. Cardiovasc. Imaging 4(9), 1002–1010 (2011).
  • Kim B-K, Kim J-S, Ko Y-G, Choi D, Jang Y, Hong M-K. Correlation of angiographic late loss with neointimal coverage of drug-eluting stent struts on follow-up optical coherence tomography. Int.J. Cardiovasc. Imaging 28(6), 1289–1297 (2012).
  • Kim JS, Fan C, Choi D et al. Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study. Int.J. Cardiol. 146(3), 341–346 (2011).
  • Kim B-K, Kim J-S, Oh C et al. Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation. Int. J. Cardiovasc. Imaging 28(4), 705–714 (2012).
  • Kim B-K, Shin D-H, Kim J-S et al. Optical coherence tomography-based evaluation of malapposed strut coverage after drug-eluting stent implantation. Int.J. Cardiovasc. Imaging 28(8), 1887–1894 (2012).
  • Kim JS, Jang IK, Kim JS et al. Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 95(23), 1907–1912 (2009).
  • Kim J-S, Kim J-S, Shin D-H et al. Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation. Int. J. Cardiovasc. Imaging 28(6), 1281–1287 (2012).
  • Kim BK, Kim JS, Park J et al. Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents. Yonsei Med. J. 53(3), 524–529 (2012).
  • Inoue T, Shite J, Yoon J et al. Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart 97(17), 1379–1384 (2011).
  • Kim JS, Kim JS, Kim TH et al. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ. J. 74(2), 320–326 (2010).
  • Cook S, Wenaweser P, Togni M et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115(18), 2426–2434 (2007).
  • Ako J, Morino Y, Honda Y et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J. Am. Coll. Cardiol. 46(6), 1002–1005 (2005).
  • Hassan AK, Bergheanu SC, Stijnen T et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur. Heart J. 31(10), 1172–1180 (2010).
  • Kim BK, Hong MK, Shin DH et al. Relationship between stent malapposition and incomplete neointimal coverage after drug-eluting stent implantation. J. Interv. Cardiol. 25(3), 270–277 (2012).
  • Cook S, Eshtehardi P, Kalesan B et al. Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation. Eur. Heart J. 33(11), 1334–1343 (2012).
  • Hong MK, Mintz GS, Lee CW et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 113(3), 414–419 (2006).
  • Hoffmann R, Morice MC, Moses JW et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart 94(3), 322–328 (2008).
  • Ko YG, Kim DM, Cho JM et al. Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. Int. J. Cardiovasc. Imaging 28(4), 715–723 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.